Kari Kendra - Concepedia

Author

Kari Kendra

Also Known As

K Haglund, K Kendra, K L Kendra, K. Kendra, K. L. Kendra, K.L. Kendra, KARI KENDRA, Kari Kendra, Kari L Kendra, Kari L kendra

263

Publications

8.2K

Citations

H-Index

108

Concepts

All Affiliations

The Ohio State University The Ohio State University Wexner Medical Center Moffitt Cancer Center The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute National Cancer Institute

About

Kari Kendra is an author at The Ohio State University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	48	2.9K
2	Health Sciences	10	10	1.1K
3	Public Health	3	3	76
4	Allergy	1	1	42
5	Biochemistry	1	1	13

Kari Kendra

Publications

7.7K

Citations

H-Index

Page 1

	Year	Citations
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma Douglas J. Schwartzentruber, David H. Lawson, Jon Richards, New England Journal of Medicine	2011	878
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma Antoni Ribas, Richard Kefford, Margaret Marshall, Journal of Clinical Oncology	2013	811
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma Sapna P. Patel, Megan Othus, Yuanbin Chen, New England Journal of Medicine	2023	741
Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Benita S. Katzenellenbogen, Kari Kendra, Mary Jane Norman, PubMed Breast OncologyChemoprevention StrategyCell ProliferationCancer BiologyLong-term Absence	1987	412
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134 Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski, Journal of Clinical Oncology	2022	402
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021 Susan M. Swetter, John A. Thompson, Mark R. Albertini, Journal of the National Comprehensive Cancer Network Nccn Guidelines® InsightsSurgical OncologyNccn Guidelines InsightsPathologyDermatology	2021	327
Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor–Mediated Natural Killer Cell Function Andrew Stiff, Prashant Trikha, Bethany L. Mundy-Bosse, Clinical Cancer Research	2018	229
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis Hamzah Abu‐Sbeih, Faisal S. Ali, Abdul Rafeh Naqash, Journal of Clinical Oncology	2019	192
Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment Andrew Stiff, Prashant Trikha, Robert Wesolowski, Cancer Research	2016	181
Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma Evanthia Galanis, Svetomir N. Markovic, Vera J. Suman, Molecular Therapy	2012	168

Page 1